ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,301 to 2,320 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Novartis MenACWY Vaccine vs Licensed Meningococcal Vaccine: serious adverse events23 of 2,649

5 of 875

0.3 points

-0.5 to 0.8

3,524NCT00450437

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

Intervention vs Control: Number of Subjects Who Discussed Disease Risk With Primary Care Provider905 of 1,673

841 of 1,847

8.6 points

5.3 to 11.8

3,520NCT01468675

Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Myocardial Reinfarction126 of 1,755

149 of 1,749

-1.3 points

-3.1 to 0.4

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis305 of 1,755

342 of 1,749

-2.2 points

-4.7 to 0.4

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Pulmonary Embolism or Deep Venous Thrombosis34 of 1,755

26 of 1,749

0.5 points

-0.4 to 1.3

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Ischemia Driven Unscheduled Coronary Revascularization39 of 1,755

43 of 1,749

-0.2 points

-1.3 to 0.8

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Composite of All-cause Mortality,Nonfatal Myocardial Reinfarction, or Unstable Angina300 of 1,755

338 of 1,749

-2.2 points

-4.8 to 0.3

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: All-cause Mortality146 of 1,755

173 of 1,749

-1.6 points

-3.5 to 0.3

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction255 of 1,755

295 of 1,749

-2.3 points

-4.7 to 0.1

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Stroke26 of 1,755

30 of 1,749

-0.2 points

-1.1 to 0.6

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: Heart Failure111 of 1,755

102 of 1,749

0.5 points

-1.1 to 2.1

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: deaths from any cause353 of 1,755

376 of 1,749

-1.4 points

-4.1 to 1.3

3,504NCT02981407

Myocardial Ischemia and Transfusion

Liberal Transfusion Strategy vs Restrictive Transfusion Strategy: serious adverse events699 of 1,755

723 of 1,749

-1.5 points

-4.8 to 1.7

3,504NCT02981407

Myocardial Ischemia and Transfusion

Group 1: Ad26.RSV.preF and RSV preF Protein vs Group 2: Placebo: Number of Participants With Unsolicited AEs up to 28 Days After Vaccination554 of 2,330

206 of 1,165

6.1 points

3.2 to 8.8

3,495NCT04908683

A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older

Part B (Blinded): Monovalent, Month 6 Hybrid Immunity vs Part B (Blinded): Bivalent, Month 6 Hybrid Immunity: Part B: Number of Participants With a First Occurrence of CDC-based COVID-19 Starting 14 Days After Month 6 Dose Until End of Follow up in RM6 Cohort Who Have Month 6 Hybrid Immunity Between Month 6 Monovalent and Bivalent Boost Groups140 of 1,732

123 of 1,759

1.1 points

-0.7 to 2.9

3,491NCT05168813

Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

Losmapimod 7.5 mg BID vs Placebo: Number of Participants Re-hospitalized Within 30 Days of Discharge213 of 1,731

210 of 1,758

0.4 points

-1.8 to 2.5

3,489NCT02145468

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Losmapimod 7.5 mg BID vs Placebo: deaths from any cause57 of 1,724

68 of 1,752

-0.6 points

-1.8 to 0.7

3,476NCT02145468

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Losmapimod 7.5 mg BID vs Placebo: serious adverse events363 of 1,724

323 of 1,752

2.6 points

-0.0 to 5.3

3,476NCT02145468

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Arm B: Anastrozol - 1 mg Per Day for 5 Years vs Arm A: Anastrozol - 1 mg Per Day for 2 Years: deaths from any cause207 of 1,738

207 of 1,732

-0.0 points

-2.2 to 2.1

3,470NCT00295620

Secondary Adjuvant Long Term Study With Arimidex

Right Ventricle Lead-Related Complications vs Summary of System and/or Procedure Related Complications Not Related to the RV Lead.: deaths from any cause323 of 1,735

323 of 1,735

0.0 points

-2.6 to 2.6

3,470NCT02235545

Optisure Lead Post Approval Study

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=116"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=116

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00450437-sae",
        "title": "Novartis MenACWY Vaccine vs Licensed Meningococcal Vaccine: serious adverse events",
        "summary": "23 of 2649 against 5 of 875; risk difference 0.3 points, 95% interval -0.5 to 0.8; NCT00450437, A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults",
        "record": "/library/comparisons/NCT00450437-sae",
        "nct_id": "NCT00450437",
        "kind": "serious-adverse-events",
        "participants": 3524,
        "risk_difference": {
          "value": 0.002968235992018551,
          "lower": -0.005155356574925693,
          "upper": 0.008381216061161132
        },
        "group_1": "23 of 2,649",
        "group_2": "5 of 875",
        "difference": "0.3 points",
        "interval": "-0.5 to 0.8",
        "trial_title": "A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults"
      },
      {
        "id": "NCT01468675-ccb91540",
        "title": "Intervention vs Control: Number of Subjects Who Discussed Disease Risk With Primary Care Provider",
        "summary": "905 of 1673 against 841 of 1847; risk difference 8.6 points, 95% interval 5.3 to 11.8; NCT01468675, Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care",
        "record": "/library/comparisons/NCT01468675-ccb91540",
        "nct_id": "NCT01468675",
        "kind": "outcome",
        "participants": 3520,
        "risk_difference": {
          "value": 0.08561143884964267,
          "lower": 0.052560917961035236,
          "upper": 0.11839824357657026
        },
        "group_1": "905 of 1,673",
        "group_2": "841 of 1,847",
        "difference": "8.6 points",
        "interval": "5.3 to 11.8",
        "trial_title": "Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=117",
  "request_id": "HVwtKAWDTADkQwhb"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?